Summary Xplico Valuation Survey

By |November, 2018|

Discount Rate versus Affiliation

In July and August 2018 Xplico conducted a survey among 600 industry professionals about valuation in the life science industry and received 79 responses. We hereby present the results of the survey.

PDF: Summary Xplico Valuation Survey – with graphs.

Xplico article for Biotech & Money / LSX

By |October, 2018|

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits:

Link to the article:

https://www.lsxleaders.com/blog/addressing-the-challenges-of-ownership-structures-in-life-sciences

Xplico named “a 2018 Gazelle Company” (a growth company) for the third year in a row by the leading Danish business newspaper Børsen.

By |October, 2018|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2018 Gazelle Company for the 3rd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years.

 

(September 2018)

XIV International Pharma Licensing Symposium, Montreux, Switzerland, September 19-21, 2018

By |September, 2018|

XIV International Pharma Licensing Symposium, Montreux, Switzerland, September 19-21, 2018

Please meet us at the  XIV International Pharma Licensing Symposium that will take place at Fairmont Le Montreux Palace in the stunning surroundings of Montreux, Switzerland. The event allows for the opportunity to hold pre-arranged partnering meetings and attend the presentations from high-calibre key note speakers. Participants also have the option of joining one of two additional training workshops being run in parallel to the one-to-one meetings.

Xplico article for Biotech & Money / LSX

By |August, 2018|

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Xplico is pleased to announce that Sisse Ramsing Escargueil has joined our team

By |August, 2018|

Xplico is pleased to announce that Sisse Ramsing Escargueil has joined our team as Executive Assistant and will be working closely together with the partners Uffe Boesen and Finn Nikolajsen.
Sisse holds a Master’s Degree in International Business Relations and has more than 18 years of experience from Sales Management (B2C and B2B) and Business Administration. She has previous experience as both Executive Assistant and Personal Assistant and has worked with business development, sales management, market analysis and financial research in Denmark, France and USA.

LSX World Congress, London, United Kingdom, February 5-6, 2019

By |August, 2018|

LSX World Congress, London, United Kingdom, February 5-6, 2019

The LSX World Congress is a high-caliber, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses. Xplico will be present to discuss your valuation needs. Please come and meet with us.

BIO-Europe Spring 2019, Vienna, Austria, March 25 – 27, 2019

By |August, 2018|

BIO-Europe Spring 2019, Vienna, Austria, March 25 – 27, 2019


Please meet us at the 2019 BIO-Europe Spring Partnering Conference in Vienna, Austria. With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe

Xplico Interview with Biotech & Money / LSX

By |July, 2018|

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.
The link to the interview: Xplico: supporting strategic decision-making through life science valuations

Xplico named “a 2017 Gazelle Company” (a growth company) for the second year in a row by the leading Danish business newspaper Børsen.

By |February, 2018|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2017 Gazelle Company for the 2nd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years.

 

(September 2017)